Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: Analysis of effects of baseline features on treatment response

Marwan Sabbagh, Jeffrey Cummings, Daniel Christensen, Rachelle Doody, Martin Farlow, Liang Liu, Joan Mackell, Randi Fain

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Treatment of Alzheimer's disease with acetylcholinesterase inhibitors can result in symptomatic benefits, but patients often show variable responses. The objective of this post hoc analysis was to investigate relationships between easily identifiable baseline characteristics/demographics and cognitive response in patients treated with either donepezil 23 mg/d or 10 mg/d and to identify factors potentially influencing response. Methods. A post hoc analysis was conducted using data from a large, 24-week, randomized, double-blind, international study enrolling patients with moderate to severe Alzheimer's disease (baseline Mini-Mental State Examination [MMSE], 0-20) (NCT 00478205). Cognitive changes in subgroups of patients based on selected baseline and demographic characteristics were compared using the least squares mean changes in Severe Impairment Battery scores at Week 24. Univariate and multivariate analyses were also performed. Results: Donepezil 23 mg/d provided statistically significant incremental cognitive benefits over donepezil 10 mg/d irrespective of baseline functional severity, measured by scores on the Alzheimer's Disease Cooperative Study-Activities of Daily Living-severe version (P <0.05). When patients were categorized by baseline cognitive severity (MMSE score), significant benefits of donepezil 23 mg/d over 10 mg/d were seen in both subgroups when based on MMSE scores of 0-9 versus 10-20 (P <0.02 and P <0.01, respectively), and in the more severe subgroup when based on MMSE scores of 0-16 versus 17-20 (P <0.0001 and P > 0.05). Statistically significant incremental cognitive benefits of donepezil 23 mg/d over 10 mg/d were also observed regardless of age, gender, weight, or prestudy donepezil 10 mg/d treatment duration (P <0.05). In the multivariate analysis, the only significant interaction was between treatment and baseline MMSE score. Conclusions: The cognitive benefits of donepezil 23 mg/d over 10 mg/d were achieved regardless of the patient's age, gender, weight, duration of prior donepezil 10 mg/d, and functional severity. The influence of baseline cognitive severity on response seemed to be dependent on the level of impairment, with cognitive benefits of donepezil 23 mg/d over 10 mg/d most apparent in those patients at a more advanced stage of disease. These data may be useful in helping practicing physicians make informed decisions for their patients with advanced Alzheimer's disease.

Original languageEnglish (US)
Article number56
JournalBMC Geriatrics
Volume13
Issue number1
DOIs
StatePublished - 2013
Externally publishedYes

Fingerprint

Alzheimer Disease
Therapeutics
Multivariate Analysis
Demography
Weights and Measures
donepezil
Cholinesterase Inhibitors
Activities of Daily Living
Least-Squares Analysis
Double-Blind Method
Physicians

Keywords

  • Alzheimer's disease
  • Cognitive dysfunction
  • Donepezil
  • Severe impairment battery (SIB)

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Medicine(all)

Cite this

Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease : Analysis of effects of baseline features on treatment response. / Sabbagh, Marwan; Cummings, Jeffrey; Christensen, Daniel; Doody, Rachelle; Farlow, Martin; Liu, Liang; Mackell, Joan; Fain, Randi.

In: BMC Geriatrics, Vol. 13, No. 1, 56, 2013.

Research output: Contribution to journalArticle

Sabbagh, Marwan ; Cummings, Jeffrey ; Christensen, Daniel ; Doody, Rachelle ; Farlow, Martin ; Liu, Liang ; Mackell, Joan ; Fain, Randi. / Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease : Analysis of effects of baseline features on treatment response. In: BMC Geriatrics. 2013 ; Vol. 13, No. 1.
@article{7e3a2c8f7534473ab961e78bffc3d7e6,
title = "Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: Analysis of effects of baseline features on treatment response",
abstract = "Background: Treatment of Alzheimer's disease with acetylcholinesterase inhibitors can result in symptomatic benefits, but patients often show variable responses. The objective of this post hoc analysis was to investigate relationships between easily identifiable baseline characteristics/demographics and cognitive response in patients treated with either donepezil 23 mg/d or 10 mg/d and to identify factors potentially influencing response. Methods. A post hoc analysis was conducted using data from a large, 24-week, randomized, double-blind, international study enrolling patients with moderate to severe Alzheimer's disease (baseline Mini-Mental State Examination [MMSE], 0-20) (NCT 00478205). Cognitive changes in subgroups of patients based on selected baseline and demographic characteristics were compared using the least squares mean changes in Severe Impairment Battery scores at Week 24. Univariate and multivariate analyses were also performed. Results: Donepezil 23 mg/d provided statistically significant incremental cognitive benefits over donepezil 10 mg/d irrespective of baseline functional severity, measured by scores on the Alzheimer's Disease Cooperative Study-Activities of Daily Living-severe version (P <0.05). When patients were categorized by baseline cognitive severity (MMSE score), significant benefits of donepezil 23 mg/d over 10 mg/d were seen in both subgroups when based on MMSE scores of 0-9 versus 10-20 (P <0.02 and P <0.01, respectively), and in the more severe subgroup when based on MMSE scores of 0-16 versus 17-20 (P <0.0001 and P > 0.05). Statistically significant incremental cognitive benefits of donepezil 23 mg/d over 10 mg/d were also observed regardless of age, gender, weight, or prestudy donepezil 10 mg/d treatment duration (P <0.05). In the multivariate analysis, the only significant interaction was between treatment and baseline MMSE score. Conclusions: The cognitive benefits of donepezil 23 mg/d over 10 mg/d were achieved regardless of the patient's age, gender, weight, duration of prior donepezil 10 mg/d, and functional severity. The influence of baseline cognitive severity on response seemed to be dependent on the level of impairment, with cognitive benefits of donepezil 23 mg/d over 10 mg/d most apparent in those patients at a more advanced stage of disease. These data may be useful in helping practicing physicians make informed decisions for their patients with advanced Alzheimer's disease.",
keywords = "Alzheimer's disease, Cognitive dysfunction, Donepezil, Severe impairment battery (SIB)",
author = "Marwan Sabbagh and Jeffrey Cummings and Daniel Christensen and Rachelle Doody and Martin Farlow and Liang Liu and Joan Mackell and Randi Fain",
year = "2013",
doi = "10.1186/1471-2318-13-56",
language = "English (US)",
volume = "13",
journal = "BMC Geriatrics",
issn = "1471-2318",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease

T2 - Analysis of effects of baseline features on treatment response

AU - Sabbagh, Marwan

AU - Cummings, Jeffrey

AU - Christensen, Daniel

AU - Doody, Rachelle

AU - Farlow, Martin

AU - Liu, Liang

AU - Mackell, Joan

AU - Fain, Randi

PY - 2013

Y1 - 2013

N2 - Background: Treatment of Alzheimer's disease with acetylcholinesterase inhibitors can result in symptomatic benefits, but patients often show variable responses. The objective of this post hoc analysis was to investigate relationships between easily identifiable baseline characteristics/demographics and cognitive response in patients treated with either donepezil 23 mg/d or 10 mg/d and to identify factors potentially influencing response. Methods. A post hoc analysis was conducted using data from a large, 24-week, randomized, double-blind, international study enrolling patients with moderate to severe Alzheimer's disease (baseline Mini-Mental State Examination [MMSE], 0-20) (NCT 00478205). Cognitive changes in subgroups of patients based on selected baseline and demographic characteristics were compared using the least squares mean changes in Severe Impairment Battery scores at Week 24. Univariate and multivariate analyses were also performed. Results: Donepezil 23 mg/d provided statistically significant incremental cognitive benefits over donepezil 10 mg/d irrespective of baseline functional severity, measured by scores on the Alzheimer's Disease Cooperative Study-Activities of Daily Living-severe version (P <0.05). When patients were categorized by baseline cognitive severity (MMSE score), significant benefits of donepezil 23 mg/d over 10 mg/d were seen in both subgroups when based on MMSE scores of 0-9 versus 10-20 (P <0.02 and P <0.01, respectively), and in the more severe subgroup when based on MMSE scores of 0-16 versus 17-20 (P <0.0001 and P > 0.05). Statistically significant incremental cognitive benefits of donepezil 23 mg/d over 10 mg/d were also observed regardless of age, gender, weight, or prestudy donepezil 10 mg/d treatment duration (P <0.05). In the multivariate analysis, the only significant interaction was between treatment and baseline MMSE score. Conclusions: The cognitive benefits of donepezil 23 mg/d over 10 mg/d were achieved regardless of the patient's age, gender, weight, duration of prior donepezil 10 mg/d, and functional severity. The influence of baseline cognitive severity on response seemed to be dependent on the level of impairment, with cognitive benefits of donepezil 23 mg/d over 10 mg/d most apparent in those patients at a more advanced stage of disease. These data may be useful in helping practicing physicians make informed decisions for their patients with advanced Alzheimer's disease.

AB - Background: Treatment of Alzheimer's disease with acetylcholinesterase inhibitors can result in symptomatic benefits, but patients often show variable responses. The objective of this post hoc analysis was to investigate relationships between easily identifiable baseline characteristics/demographics and cognitive response in patients treated with either donepezil 23 mg/d or 10 mg/d and to identify factors potentially influencing response. Methods. A post hoc analysis was conducted using data from a large, 24-week, randomized, double-blind, international study enrolling patients with moderate to severe Alzheimer's disease (baseline Mini-Mental State Examination [MMSE], 0-20) (NCT 00478205). Cognitive changes in subgroups of patients based on selected baseline and demographic characteristics were compared using the least squares mean changes in Severe Impairment Battery scores at Week 24. Univariate and multivariate analyses were also performed. Results: Donepezil 23 mg/d provided statistically significant incremental cognitive benefits over donepezil 10 mg/d irrespective of baseline functional severity, measured by scores on the Alzheimer's Disease Cooperative Study-Activities of Daily Living-severe version (P <0.05). When patients were categorized by baseline cognitive severity (MMSE score), significant benefits of donepezil 23 mg/d over 10 mg/d were seen in both subgroups when based on MMSE scores of 0-9 versus 10-20 (P <0.02 and P <0.01, respectively), and in the more severe subgroup when based on MMSE scores of 0-16 versus 17-20 (P <0.0001 and P > 0.05). Statistically significant incremental cognitive benefits of donepezil 23 mg/d over 10 mg/d were also observed regardless of age, gender, weight, or prestudy donepezil 10 mg/d treatment duration (P <0.05). In the multivariate analysis, the only significant interaction was between treatment and baseline MMSE score. Conclusions: The cognitive benefits of donepezil 23 mg/d over 10 mg/d were achieved regardless of the patient's age, gender, weight, duration of prior donepezil 10 mg/d, and functional severity. The influence of baseline cognitive severity on response seemed to be dependent on the level of impairment, with cognitive benefits of donepezil 23 mg/d over 10 mg/d most apparent in those patients at a more advanced stage of disease. These data may be useful in helping practicing physicians make informed decisions for their patients with advanced Alzheimer's disease.

KW - Alzheimer's disease

KW - Cognitive dysfunction

KW - Donepezil

KW - Severe impairment battery (SIB)

UR - http://www.scopus.com/inward/record.url?scp=84878507678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878507678&partnerID=8YFLogxK

U2 - 10.1186/1471-2318-13-56

DO - 10.1186/1471-2318-13-56

M3 - Article

C2 - 23742728

AN - SCOPUS:84878507678

VL - 13

JO - BMC Geriatrics

JF - BMC Geriatrics

SN - 1471-2318

IS - 1

M1 - 56

ER -